Spruce Biosciences Q3 net loss $12.4M; completes enrollment in two key CAH trials

SPRUCE BIOSCIENCES, INC.

2023-Q3 EPS reported -$1.01 revenue$7,202,000

Net loss $12.4M for Q3 2023 vs. $11.4M same period 2022; revenue $3.1M (Kaken collaboration).
Cash, equivalents, investments $108.0M; expected to fund operations into H1 2025.
Enrollment completed in CAHptain-205 (pediatric, 30 patients) and CAHmelia-203 (adult, >72 patients).
CAHmelia-204 enrollment >75% on track for early Q1 2024 completion.
Topline data expected Q1 2024 for CAHmelia-203 & CAHptain-205; Q3 2024 for CAHmelia-204.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income $12.4 million.

Period: the third quarter ended September 30, 2023
Net income: $12.4 million
Result: reported results

Exact text from the filing

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-062936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.